Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.

doi:10.1158/1078-0432.CCR-16-1779

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2017

Zembutsu Hitoshi, Nakamura Seigo, Akashi-Tanaka Sadako, Kuwayama Takashi, Watanabe Chie, Takamaru Tomoko, Takei Hiroyuki, Ishikawa Takashi, Miyahara Kana, Matsumoto Hiroshi, Hasegawa Yoshie, Kutomi Goro, Shima Hiroaki, Satomi Fukino, Okazaki Minoru, Zaha Hisamitsu, Onomura Mai, Matsukata Ayami, Sagara Yasuaki, Baba Shinichi, Yamada Akimitsu, Shimada Kazuhiro, Shimizu Daisuke, Tsugawa Koichiro, Shimo Arata, Tan Ern Yu, Hartman Mikael, Chan Ching-Wan, Lee Soo Chin, Nakamura Yusuke

Abstract excerpt

Purpose: CYP2D6 is the key enzyme responsible for the generation of the potent active metabolite of tamoxifen, "endoxifen." There are still controversial reports questioning the association between CYP2D6 genotype and tamoxifen efficacy. Hence, we performed a prospective multicenter study to evaluate the clinical effect of CYP2D6 genotype on tamoxifen therapy.Experimental Design: We enrolled 279 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antineoplastic Agents, Hormonal

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2D6

Share to Ki-67 Antigen

Share to Tamoxifen

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 27797974
DOI: 10.1158/1078-0432.CCR-16-1779

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.PMID 27797974Read ↗

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.Semantic proximity Read ↗

CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons LearnedSemantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.Semantic proximity Read ↗

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.Semantic proximity Read ↗

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.